kavin submitted, created time 5 months 2 days (www.diabeteshealth.com)

Drug manufacturer Novo Nordisk has applied to the U.S. Federal Drug Administration and the European Medicines Agency for approval of liraglutide, a human GLP-1 analog that is taken once daily for the treatment of type 2 diabetes.

The company’s applications are based on a study of 6,500 type 2s, 4,200 of whom received liraglutide as a diet and exercise adjunct. Some of the drug’s recipients used it in combination with other medications used to treat diabetes, while others received it as a monotherapy

3 comments | Blog It | Email It | Keywords: Type 2 diabetes FDA insulin drug approval process combination therapy monotherapy diabetes liraglutide GLP-1